Compare DTST & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTST | PMCB |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | 55 | 2 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.7M |
| IPO Year | N/A | 2001 |
| Metric | DTST | PMCB |
|---|---|---|
| Price | $4.18 | $0.82 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 226.7K |
| Earning Date | 04-14-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 277.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.25 | $0.63 |
| 52 Week High | $5.44 | $1.51 |
| Indicator | DTST | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 53.31 |
| Support Level | $3.91 | $0.65 |
| Resistance Level | $4.34 | $1.05 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 30.17 | 45.45 |
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.